Coronary disease is a major cause of death and morbidity in developed countries.
Coronary disease is a major cause of death and morbidity in developed countries. 1 It is now well established that coronary disease develops subclinically over several decades thereby providing ample opportunities for a timely prevention. In fact, coronary atherosclerotic plaques are present in the majority of individuals after the age of 30 years as evidenced both by studies at autopsy or intracoronary imaging studies using intravascular ultrasound. 2 Moreover, recent genetic studies strongly support the concept that lifelong lower low-density lipoprotein (LDL) cholesterol levels or arterial blood pressure are associated with a marked lifetime reduction (>80%) in the risk of coronary disease, 3, 4 indicating that coronary disease is largely preventable. This is also supported by a recent coronary computed tomography (CT) study in a population with a very low burden of cardiovascular risk factors, demonstrating that in the absence of cardiovascular risk factors the prevalence of coronary disease as evaluated by coronary CT is very low. 5 These data clearly suggest that early prevention of coronary disease is possible and will likely be more effective. Moreover, primordial coronary disease prevention is also important given the knowledge that myocardial infarction or sudden cardiac death are frequently the first clinical presentations of coronary disease. 6 Currently used scores for cardiovascular risk prediction are largely focusing on conventional risk factors and perform well at a population level but are relatively less efficient at the individual level. However, there is the hope and need for a more precise and personalised coronary disease risk assessment involving the earlier detection of significant subclinical coronary disease (i.e. identify the susceptible subject). In the present issue of the European Journal of Preventive Cardiology Bittencourt et al. report an analysis from the MultiEthnic Study of Atherosclerosis (MESA), indicating that the analysis of the coronary artery calcium (CAC) score can modify the absolute risk of cardiovascular mortality over 10 years in comparison to the European guideline recommended SCORE cardiovascular risk assessment approach. 7 In the group of patients who would not be recommended for lipid-lowering therapy based on their SCORE risk and LDL-cholesterol levels alone according to current European guideline recommendations, i.e. who would be considered to be at low cardiovascular risk without imaging, there was a subgroup of individuals with a CAC score greater than 100 who had a markedly increased 10-year cardiovascular mortality (>10%), although this subgroup was rather small, i.e. 6% of these individuals. Clearly, identification of the presence of significant coronary plaques, e.g. with a CAC score greater than 100, will most likely identify individuals at higher cardiovascular risk who will particularly benefit from earlier preventive strategies, such as more intense lipid lowering. In a recent study in 318 asymptomatic sportsmen (!45 years) who underwent coronary CT 16.4% had a CAC score greater than 100, i.e. indicating a somewhat higher percentage in asymptomatic middle-aged male subjects (average age 54.7 years) as compared to the individuals of the MESA study. 8 Of note, the current European guidelines do recommend earlier lipid lowering also in individuals with detected significant coronary plaques, because these individuals would be considered at very high cardiovascular risk according to the European guidelines. 9, 10 It should also be considered that recent analyses from the Progression of Early Subclinical Atherosclerosis (PESA) study indicated that many conventional cardiovascular risk factor free (as defined currently) middle-aged individuals (>40%) had subclinical atherosclerosis, when combined ultrasound-detected carotid, iliofemoral and abdominal aortic plaques and coronary artery calcification were evaluated, 11 indicating that despite a negative CAC score, systemic atherosclerosis may already be present in other vascular territories. Notably, LDL-cholesterol, even at levels currently considered normal, was independently associated with the presence and extent of early systemic atherosclerosis in the absence of major cardiovascular risk factors in the PESA study. 11 These findings further support a more effective LDL-cholesterol lowering for primordial prevention in individuals conventionally considered at optimal risk, who already have subclinical atherosclerosis.
In the analysis of Bittencourt et al. the absence of CAC was associated with a reduced cardiovascular mortality in all groups, 7 also in the group of subjects for which lipid-lowering therapy would be recommended according to current European guidelines based on SCORE and LDL-cholesterol levels alone. 9, 10 These data further support the concept that CAC imaging can help in being more precise and personalised in individual cardiovascular risk assessment. However, given the above observations, i.e. that ultrasound assessment indicates atherosclerosis in patients with a CAC score of 0 in other vascular beds in the PESA study and that life-long lower LDL-cholesterol levels are associated with a dramatic reduction of the life-time risk of coronary disease, 3 one would be cautious to discourage in general LDL lowering in these patients, also taking into account that the risk assessment is related to the 10-year risk but not to the life-time cardiovascular risk. Nevertheless, the analysis of Bittencourt et al. indicates that CAC score assessment can help in being more precise with the individual 10-year risk assessment, which could for example aid in determining the intensity of lipid lowering to be recommended and is consistent with the finding that the CAC score adds to the predictive power of the main risk factors for atherosclerotic cardiovascular disease.
Increasing data indicate that imaging of significant subclinical coronary and systemic atherosclerosis can help us in becoming more accurate and personalised in our cardiovascular risk assessment and the subsequent recommendations for preventive measures including the intensity of lipid lowering. This is at present particularly relevant for individuals who are borderline for lipid-lowering treatment or in whom there is doubt about the appropriate cardiovascular risk assessment based on conventional cardiovascular risk factors, e.g. in individuals with a positive family history of atherosclerotic cardiovascular disease. In the current endeavours shall we perform CAC in all subjects to guide our intervention strategy? This strategy would be strongly supported by a prospective trial based on CAC risk stratification to evaluate the effects of LDL lowering, and we also need to consider that CAC is increased by statin treatment. This information is urgently needed before fully embedding CAC determination in our general approach to assess and control cardiovascular risk in all individuals.
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